1. Home
  2. ACRS vs MAXN Comparison

ACRS vs MAXN Comparison

Compare ACRS & MAXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • MAXN
  • Stock Information
  • Founded
  • ACRS 2012
  • MAXN 2019
  • Country
  • ACRS United States
  • MAXN Singapore
  • Employees
  • ACRS N/A
  • MAXN N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • MAXN Semiconductors
  • Sector
  • ACRS Health Care
  • MAXN Technology
  • Exchange
  • ACRS Nasdaq
  • MAXN Nasdaq
  • Market Cap
  • ACRS 132.0M
  • MAXN 118.1M
  • IPO Year
  • ACRS 2015
  • MAXN N/A
  • Fundamental
  • Price
  • ACRS $2.60
  • MAXN $6.53
  • Analyst Decision
  • ACRS Strong Buy
  • MAXN Sell
  • Analyst Count
  • ACRS 5
  • MAXN 6
  • Target Price
  • ACRS $11.00
  • MAXN $195.80
  • AVG Volume (30 Days)
  • ACRS 956.3K
  • MAXN 469.0K
  • Earning Date
  • ACRS 02-25-2025
  • MAXN 12-05-2024
  • Dividend Yield
  • ACRS N/A
  • MAXN N/A
  • EPS Growth
  • ACRS N/A
  • MAXN N/A
  • EPS
  • ACRS N/A
  • MAXN N/A
  • Revenue
  • ACRS $27,079,000.00
  • MAXN $689,010,000.00
  • Revenue This Year
  • ACRS N/A
  • MAXN N/A
  • Revenue Next Year
  • ACRS N/A
  • MAXN $9.27
  • P/E Ratio
  • ACRS N/A
  • MAXN N/A
  • Revenue Growth
  • ACRS 26.35
  • MAXN N/A
  • 52 Week Low
  • ACRS $0.95
  • MAXN $4.98
  • 52 Week High
  • ACRS $5.17
  • MAXN $602.00
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 44.33
  • MAXN 44.58
  • Support Level
  • ACRS $2.31
  • MAXN $6.01
  • Resistance Level
  • ACRS $2.64
  • MAXN $6.90
  • Average True Range (ATR)
  • ACRS 0.16
  • MAXN 0.62
  • MACD
  • ACRS 0.02
  • MAXN -0.06
  • Stochastic Oscillator
  • ACRS 58.76
  • MAXN 20.89

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

About MAXN Maxeon Solar Technologies Ltd.

Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, France, Italy, and others.

Share on Social Networks: